Alteplase (Activase), an intravenous (IV) tissue plasminogen activator (tPA), is the only FDA-approved thrombolytic agent for acute ischemic stroke (AIS). Recently updated American Heart Association/American Stroke Association (AHA/ASA) Guidelines for the Early Management of Patients with Acute Ischemic Stroke and revisions to Activase labeling have expanded the time window eligibility for tPA treatment and have loosened contraindications surrounding tPA treatment. These changes should promote increased utilization of tPA in AIS, resulting in more instances of timely reperfusion and reduction of neurologic sequelae
The coronavirus disease 2019 (COVID-19) pandemic has prompted the creation of new therapies to help ...
Alzheimer’s disease (AD) is the sixth leading cause of death in the United States with approximately...
Context According to published articles, thrombosis is the main reason for death all over ...
Alteplase (Activase), an intravenous (IV) tissue plasminogen activator (tPA), is the only FDA-approv...
Background: Vitamin K antagonist (VKA)–associated intracerebral hemorrhages (ICHs) are more likely t...
Tumor necrosis factor (TNF)-α is produced in brain in response to acute cerebral ischemia, and promo...
They should consider many factors and use clear guidance on predicting phenotypes from genotypes to ...
Dr. Mehvar responds to misinterpretations of his previous research in Yang et al. (2015)
Editorial on the Research Topic Adenylyl cyclase isoforms as potential drug target
In 2001, the ISMP and the Pediatric Pharmacy Advocacy Group (PPAG) collaborated to produce the natio...
The result is the following report, which explores the role of academic pharmacy in preceptor contin...
Speech delivered by Lawrence “LB” Brown, incoming President of the American Pharmacists Association,...
Antiarrhythmic therapy for atrial fibrillation comprises a broad range of medications that are used ...
Given the recent emphasis of the academy on active engagement of learners in their own learning and ...
Background: Cerebral microbleeds (CMB) are MRI-demonstrable cerebral microhemorrhages (CMH) which co...
The coronavirus disease 2019 (COVID-19) pandemic has prompted the creation of new therapies to help ...
Alzheimer’s disease (AD) is the sixth leading cause of death in the United States with approximately...
Context According to published articles, thrombosis is the main reason for death all over ...
Alteplase (Activase), an intravenous (IV) tissue plasminogen activator (tPA), is the only FDA-approv...
Background: Vitamin K antagonist (VKA)–associated intracerebral hemorrhages (ICHs) are more likely t...
Tumor necrosis factor (TNF)-α is produced in brain in response to acute cerebral ischemia, and promo...
They should consider many factors and use clear guidance on predicting phenotypes from genotypes to ...
Dr. Mehvar responds to misinterpretations of his previous research in Yang et al. (2015)
Editorial on the Research Topic Adenylyl cyclase isoforms as potential drug target
In 2001, the ISMP and the Pediatric Pharmacy Advocacy Group (PPAG) collaborated to produce the natio...
The result is the following report, which explores the role of academic pharmacy in preceptor contin...
Speech delivered by Lawrence “LB” Brown, incoming President of the American Pharmacists Association,...
Antiarrhythmic therapy for atrial fibrillation comprises a broad range of medications that are used ...
Given the recent emphasis of the academy on active engagement of learners in their own learning and ...
Background: Cerebral microbleeds (CMB) are MRI-demonstrable cerebral microhemorrhages (CMH) which co...
The coronavirus disease 2019 (COVID-19) pandemic has prompted the creation of new therapies to help ...
Alzheimer’s disease (AD) is the sixth leading cause of death in the United States with approximately...
Context According to published articles, thrombosis is the main reason for death all over ...